Archives
-
o2h Ventures Participates in Oversubscribed Seed Round to Advance CamGene Therapeutics’ RNA-Based Medicines
03 November, 2025
-
o2h Ventures Portfolio Update: Monument Therapeutics Reaches Landmark Milestone in Schizophrenia
23 August, 2025
-
o2h Ventures Makes SEIS investment in Sansanima, A University of Sheffield Spinout Developing Alternatives to Animal Testing
28 May, 2025
-
o2h Ventures Shortlisted for ‘Seed VC of the Year’ at UKBAA Angel Investment Awards 2025
14 May, 2025
-
o2h Ventures Backs Enedra Therapeutics, Targeting Complex Cancers
07 May, 2025
-
o2h Ventures Makes a Follow-on Investment in Qkine, the Cambridge-based Specialist in Growth Factor Manufacturing
21 March, 2025
-
Monument Tx Advances Schizophrenia Treatment with £850K Funding Round; o2h Ventures Makes Follow-On Investment
25 February, 2025
-
o2h Ventures Makes an Investment in Atelerix, an Innovative Gel-Based Tech to Preserve Live Cells
29 January, 2025
-
o2h Ventures Invests in Revolver Therapeutics Revolutionising Childhood Cancer Treatment
10 December, 2024